Overcoming chemoresistance in pancreatic cancer cells: Role of the bitter taste receptor T2R10

Journal of Cancer

Volumn 9, Issue 4, 2018, Pages 711-725

  Stern, Louisa ^a   Giese, Nathalia ^a   Hackert, Thilo ^a   Strobel, Oliver ^a   Schirmacher, Peter ^a   Felix, Klaus ^a   Gaida, Matthias M ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Bitter receptors; Caffeine; Chemoresistance; Pancreatic cancer

Indexed keywords

BITTER TASTE RECEPTOR T2R10; BREAST CANCER RESISTANCE PROTEIN; CAFFEINE; FLUOROURACIL; GEMCITABINE; GUANINE NUCLEOTIDE BINDING PROTEIN; MEMBRANE PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; BITTER TASTE; BXPC-3 CELL LINE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CELL DEATH; DOWN REGULATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL;

EID: 85042196739     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.21803     Document Type: Article

References (65)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015; 65: 5-29.
2. Spadi R, Brusa F, Ponzetti A, Chiappino I, Birocco N, Ciuffreda L, et al. Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World J Clin Oncol. 2016; 7: 27-43.
3. Chand S, O'Hayer K, Blanco FF, Winter JM, Brody JR. The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. International journal of biological sciences. 2016; 12: 273-82.
4. Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G, et al. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncology reports. 2010; 23: 1183-92.
5. Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, et al. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. International journal of cancer Journal international du cancer. 2010; 127: 257-68.
6. Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S, et al. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer research. 2009; 69: 5575-83.
7. Banerjee S, Wang Z, Kong D, Sarkar FH. 3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer research. 2009; 69: 5592-600.
8. Zhang JG, Zhao G, Qin Q, Wang B, Liu L, Liu Y, et al. Nicotinamide prohibits proliferation and enhances chemosensitivity of pancreatic cancer cells through deregulating SIRT1 and Ras/Akt pathways. Pancreatotomy: official journal of the International Association of Pancreatology. 2013; 13: 140-6.
9. El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, Sarkar FH. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer research. 2006; 66: 10553-9.
10. Adler E, Hoon MA, Mueller KL, Chandrashekar J, Ryba NJ, Zuker CS. A novel family of mammalian taste receptors. Cell. 2000; 100: 693-702.
11. Behrens M, Meyerhof W. Bitter taste receptors and human bitter taste perception. Cellular and molecular life sciences: CMLS. 2006; 63: 1501-9.
12. Meyerhof W, Batram C, Kuhn C, BrockhoffA, Chudoba E, Bufe B, et al. The molecular receptive ranges of human TAS2R bitter taste receptors. Chem Senses. 2010; 35: 157-70.
13. Behrens M, Meyerhof W. Bitter taste receptor research comes of age: from characterization to modulation of TAS2Rs. Seminars in cell & developmental biology. 2013; 24: 215-21.
14. Behrens M, Gunn HC, Ramos PC, Meyerhof W, Wooding SP. Genetic, functional, and phenotypic diversity in TAS2R38-mediated bitter taste perception. Chemical senses. 2013; 38: 475-84.
15. Narukawa M, Noga C, Ueno Y, Sato T, Misaka T, Watanabe T. Evaluation of the bitterness of green tea catechins by a cell-based assay with the human bitter taste receptor hTAS2R39. Biochemical and biophysical research communications. 2011; 405: 620-5.
16. Gaida MM, Dapunt U, Hansch GM. Sensing developing biofilms: the bitter receptor T2R38 on myeloid cells. Pathogens and disease. 2016; 74.
17. Shah AS, Ben-Shahar Y, Moninger TO, Kline JN, Welsh MJ. Motile cilia of human airway epithelia are chemosensory. Science (New York, NY). 2009; 325: 1131-4.
18. Singh N, Chakraborty R, Bhullar RP, Chelikani P. Differential expression of bitter taste receptors in non-cancerous breast epithelial and breast cancer cells. Biochemical and biophysical research communications. 2014; 446: 499-503.
19. Latorre R, Huynh J, Mazzoni M, Gupta A, Bonora E, Clavenzani P, et al. Expression of the Bitter Taste Receptor, T2R38, in Enteroendocrine Cells of the Colonic Mucosa of Overweight/Obese vs. Lean Subjects. PloS one. 2016; 11: e0147468.
20. Wolfle U, Elsholz FA, Kersten A, Haarhaus B, Schumacher U, Schempp CM. Expression and Functional Activity of the Human Bitter Taste Receptor TAS2R38 in Human Placental Tissues and JEG-3 Cells. Molecules. 2016; 21.
21. Singh N, Vrontakis M, Parkinson F, Chelikani P. Functional bitter taste receptors are expressed in brain cells. Biochemical and biophysical research communications. 2011; 406: 146-51.
22. Lee RJ, Kofonow JM, Rosen PL, Siebert AP, Chen B, Doghramji L, et al. Bitter and sweet taste receptors regulate human upper respiratory innate immunity. The Journal of clinical investigation. 2014; 124: 1393-405.
23. Manson ML, Safholm J, Al-Ameri M, Bergman P, Orre AC, Sward K, et al. Bitter taste receptor agonists mediate relaxation of human and rodent vascular smooth muscle. European journal of pharmacology. 2014; 740: 302-11.
24. Jing F, Liu M, Yang N, Liu Y, Li X, Li J. Relaxant effect of chloroquine in rat ileum: possible involvement of nitric oxide and BKCa. The Journal of pharmacy and pharmacology. 2013; 65: 847-54.
25. Zhang CH, Lifshitz LM, Uy KF, Ikebe M, Fogarty KE, ZhuGe R. The cellular and molecular basis of bitter tastant-induced bronchodilation. PLoS biology. 2013; 11: e1001501.
26. Tan X, Sanderson MJ. Bitter tasting compounds dilate airways by inhibiting airway smooth muscle calcium oscillations and calcium sensitivity. British journal of pharmacology. 2014; 171: 646-62.
27. Gaida MM, Mayer C, Dapunt U, Stegmaier S, Schirmacher P, Wabnitz GH, et al. Expression of the bitter receptor T2R38 in pancreatic cancer: localization in lipid droplets and activation by a bacteria-derived quorum-sensing molecule. Oncotarget. 2016.
28. Kwatra D, Venugopal A, Standing D, Ponnurangam S, Dhar A, Mitra A, et al. Bitter melon extracts enhance the activity of chemotherapeutic agents through the modulation of multiple drug resistance. Journal of pharmaceutical sciences. 2013; 102: 4444-54.
29. Lyn-Cook BD, Rogers T, Yan Y, Blann EB, Kadlubar FF, Hammons GJ. Chemopreventive effects of tea extracts and various components on human pancreatic and prostate tumor cells in vitro. Nutrition and cancer. 1999; 35: 80-6.
30. Ding R, Shi J, Pabon K, Scotto KW. Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance. Molecular pharmacology. 2012; 81: 328-37.
31. Kawano Y, Nagata M, Kohno T, Ichimiya A, Iwakiri T, Okumura M, et al. Caffeine increases the antitumor effect of Cisplatin in human hepatocellular carcinoma cells. Biological & pharmaceutical bulletin. 2012; 35: 400-7.
32. Mei Y, Wei D, Liu J. Reversal of cancer multidrug resistance by tea polyphenol in KB cells. Journal of chemotherapy. 2003; 15: 260-5.
33. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 1998; 11: 155-68.
34. Gaida MM, Welsch T, Herpel E, Tschaharganeh DF, Fischer L, Schirmacher P, et al. MHC class II expression in pancreatic tumors: a link to intratumoral inflammation. Virchows Arch. 2012; 460: 47-60.
35. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008; 5: 621-8.
36. Morgan RT, Woods LK, Moore GE, Quinn LA, McGavran L, Gordon SG. Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma. International journal of cancer Journal international du cancer. 1980; 25: 591-8.
37. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58: 621-81.
38. Thermo Fisher Scientific. User Guide: Pierce BCA Protein Assay Rockford, IL, USA.
39. Kim Y, Han D, Min H, Jin J, Yi EC, Kim Y. Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines. Molecules and cells. 2014; 37: 888-98.
40. Sharma P, Panebra A, Pera T, Tiegs BC, Hershfeld A, Kenyon LC, et al. Antimitogenic effect of bitter taste receptor agonists on airway smooth muscle cells. American journal of physiology Lung cellular and molecular physiology. 2016; 310: L365-76.
41. Fahy BN, Schlieman M, Virudachalam S, Bold RJ. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. British journal of cancer. 2003; 89: 391-7.
42. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2002; 5: 234-48.
43. Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clinical cancer research: an official journal of the American Association for Cancer Research. 2001; 7: 3269-75.
44. Huang FF, Zhang L, Wu DS, Yuan XY, Yu YH, Zhao XL, et al. PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia. PLoS One. 2014; 9: e88298.
45. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell stem cell. 2009; 4: 226-35.
46. Allen JD, Schinkel AH. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Molecular cancer therapeutics. 2002; 1: 427-34.
47. Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochemical pharmacology. 2012; 83: 1084-103.
48. Mo W, Zhang JT. Human ABCG2: structure, function, and its role in multidrug resistance. International journal of biochemistry and molecular biology. 2012; 3: 1-27.
49. Doyle L, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003; 22: 7340-58.
50. Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, Le Marchand L, Henderson BE. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology. 2015; 148: 118-25; quiz e15.
51. Alam MS, Gaida MM, Bergmann F, Lasitschka F, Giese T, Giese NA, et al. Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression. Nature medicine. 2015; 21: 1337-43.
52. Mundi PS, Sachdev J, McCourt C, Kalinsky K. AKT in cancer: new molecular insights and advances in drug development. British journal of clinical pharmacology. 2016.
53. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2: 489-501.
54. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129: 1261-74.
55. Jiang SJ, Hsu SY, Deng CR, Huang HC, Liu SL, Shi GY, et al. Dextromethorphan attenuates LPS-induced adhesion molecule expression in human endothelial cells. Microcirculation. 2013; 20: 190-201.
56. Hamada S, Satoh K, Hirota M, Kanno A, Umino J, Ito H, et al. The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2. J Cell Physiol. 2012; 227: 729-38.
57. Lee SH, Kim H, Hwang JH, Lee HS, Cho JY, Yoon YS, et al. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients. Pathology international. 2012; 62: 167-75.
58. Yuan Y, Yang Z, Miao X, Li D, Liu Z, Zou Q. The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma. Tumour Biol. 2015; 36: 9961-8.
59. Wells JN, Miller JR. Methylxanthine inhibitors of phosphodiesterases. Methods in enzymology. 1988; 159: 489-96.
60. Sawynok J, Yaksh TL. Caffeine as an Analgesic Adjuvant - a Review of Pharmacology and Mechanisms of Action. Pharmacol Rev. 1993; 45: 43-85.
61. Sutherland EW, Rall TW. Fractionation and Characterization of a Cyclic Adenine Ribonucleotide Formed by Tissue Particles. Journal of Biological Chemistry. 1958; 232: 1077-91.
62. Cho-Chung YS, Pepe S, Clair T, Budillon A, Nesterova M. cAMP-dependent protein kinase: role in normal and malignant growth. Crit Rev Oncol Hematol. 1995; 21: 33-61.
63. Zhao H, Wei R, Wang L, Tian Q, Tao M, Ke J, et al. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. Am J Physiol Endocrinol Metab. 2014; 306: E1431-41.
64. Lorenz R, Aleksic T, Wagner M, Adler G, Weber CK. The cAMP/Epac1/Rap1 pathway in pancreatic carcinoma. Pancreas. 2008; 37: 102-3.
65. Naim M, Seifert R, Nurnberg B, Grunbaum L, Schultz G. Some taste substances are direct activators of G-proteins. The Biochemical journal. 1994; 297 (Pt 3): 451-4.